Actelion Ltd (ALIOF) 168.0000 $ALIOF 3 Dirt-Cheap

New Post Public Reply Private Reply Replies (0) Message Board

Jun 5, 2016 at 3:12 PM

Actelion Ltd (ALIOF) 168.0000 $ALIOF

3 Dirt-Cheap Biotech Stocks To Buy
Todd Campbell, The Motley Fool - Motley Fool - Wed May 04, 8:17AM CDT
SOURCE: FLICKR USER ELLIOTT BROWN Sometimes stocks sell down to prices that look too good to be true, but just because a company appears cheap doesn't mean that its a good value. For a company to be a bargain that's really worth buying, there needs...
ENDP: 17.59 (+0.15), GILD: 86.15 (-0.57), MRK: 56.64 (-0.18), UTHR: 116.31 (-4.72)

Actelion's Annual General Meeting of Shareholders held in Basel, Switzerland - All Board proposals approved
Globe Newswire - Wed May 04, 5:00AM CDT
Actelion Pharmaceuticals Ltd / Actelion's Annual General Meeting of Shareholders held in Basel, Switzerland - All Board proposals approved . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

United (UTHR) Stock Declines Despite Q1 Earnings Beat
Arpita Dutt - Zacks Investment Research - Fri Apr 29, 10:54AM CDT
Although United Therapeutics (UTHR) delivered an earnings beat, shares were down on the revenue miss.
EBS: 43.71 (+0.07), UTHR: 116.31 (-4.72), AEGR: 1.71 (-0.05)

Very strong performance continues in the first quarter of 2016 - driven by outcome-based PAH portfolio
Globe Newswire - Thu Apr 21, 12:01AM CDT
Actelion Pharmaceuticals Ltd / Very strong performance continues in the first quarter of 2016 - driven by outcome-based PAH portfolio . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

Clovis Hits 52-week Low Post Rociletinib Briefing Documents
Zacks Equity Research - Zacks Investment Research - Mon Apr 11, 2:45PM CDT
Clovis Oncology's (CLVS) shares touched a 52-week low with the FDA raising concerns related to the lung cancer treatment, rociletinib, in its briefing documents.
EBS: 43.71 (+0.07), CLVS: 16.30 (-0.97), ANIK: 47.49 (-0.22)

Ionis Tanks, FDA Clinical Hold on IONIS-TTRRx Phase III Study
Zacks Equity Research - Zacks Investment Research - Fri Apr 08, 3:40PM CDT
Ionis Pharmaceuticals' (IONS) shares plunged 11% after the FDA placed a clinical hold on the phase III CARDIO-TTR study on IONIS-TTRRx.
BIIB: 290.23 (+0.50), GSK: 42.89 (+0.48), IONS: 22.96 (-0.79)

Intercept's (ICPT) Ocaliva Gets Favorable FDA Panel Vote
Zacks Equity Research - Zacks Investment Research - Fri Apr 08, 2:35PM CDT
Intercept Pharmaceuticals, Inc. (ICPT) announced that the FDA's Gastrointestinal Drugs Advisory Committee has voted unanimously in favor of the company's lead pipeline candidate, Ocaliva.
ARQL: 1.82 (-0.03), SCMP: 11.99 (-0.42), ICPT: 167.37 (-0.29)

Illumina Unveils BaseSpace Suite, Boosts Precision Medicine
Zacks Equity Research - Zacks Investment Research - Fri Apr 08, 12:55PM CDT
Illumina, Inc. (ILMN) recently launched its BaseSpace Informatics suite to facilitate precision medicine and genomics research.
ILMN: 145.54 (-1.56), AMAG: 21.57 (-0.62), ANIK: 47.49 (-0.22)

Seres Therapeutics (MCRB) in Focus: Stock Up 5.5% in Session
Zacks Equity Research - Zacks Investment Research - Fri Apr 08, 7:35AM CDT
Seres Therapeutics, Inc. (MCRB) was a big mover last session, as the company saw its shares rise around 6% on the day.
MCRB: 29.92 (-2.18)

Ironwood Slumps, Halts Development of Gastroparesis Drug
Zacks Equity Research - Zacks Investment Research - Wed Apr 06, 9:10AM CDT
Ironwood Pharmaceuticals (IRWD) plans to discontinue the development of IW-9179 for diabetic gastroparesis after unfavorable phase IIa study results; shares fall.
IRWD: 12.95 (-0.26), EBS: 43.71 (+0.07), AMAG: 21.57 (-0.62)

Actelion issues invitation to 2016 Annual General Meeting of Shareholders
Globe Newswire - Wed Apr 06, 12:01AM CDT
Actelion Pharmaceuticals Ltd / Actelion issues invitation to 2016 Annual General Meeting of Shareholders . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

AbbVie Up, Wins CHMP Backing for Humira's Expanded Use
Zacks Equity Research - Zacks Investment Research - Tue Apr 05, 10:20AM CDT
AbbVie Inc. (ABBV) announced that the EMA's CHMP has rendered an opinion in favor of expanding Humira's label in the EU.
EBS: 43.71 (+0.07), ABBV: 65.00 (-0.09), AMAG: 21.57 (-0.62)

Abeona Therapeutics (ABEO) Jumps: Stock Rises 6.4%
Zacks Equity Research - Zacks Investment Research - Tue Apr 05, 7:40AM CDT
Abeona Therapeutics Inc. (ABEO) saw its shares rise above 6% in the last trading session.
ABEO: 3.03 (-0.01)

Bristol-Myers Gets CHMP Backing for Opdivo's Expanded Use
Zacks Equity Research - Zacks Investment Research - Mon Apr 04, 3:10PM CDT
Bristol-Myers' (BMY) Opdivo gets CHMP backing for label expansion of Opdivo in combination with Yervoy for advanced (unresectable or metastatic) melanoma.
AMAG: 21.57 (-0.62), BMY: 72.89 (-0.11), ANIK: 47.49 (-0.22)

Regeneron, Sanofi Up, Eczema Drug Tops Phase III Studies
Zacks Equity Research - Zacks Investment Research - Mon Apr 04, 2:40PM CDT
Regeneron Pharmaceuticals (REGN) and Sanofi's atopic dermatitis candidate dupilumab scores in phase III studies; shares up.
AMAG: 21.57 (-0.62), SNY: 41.14 (-0.03), REGN: 400.75 (-6.38)

The Zacks Analyst Blog Highlights: Actelion, Mesoblast, Kindred Biosciences and CorMedix
Zacks Equity Research - Zacks Investment Research - Mon Apr 04, 8:30AM CDT
The Zacks Analyst Blog Highlights: Actelion, Mesoblast, Kindred Biosciences and CorMedix
CRMD: 2.72 (+0.01), MESO: 7.07 (+0.16), KIN: 4.05 (-0.01)

VIVUS (VVUS) in Focus: Stock Jumps 6.4% in Session
Zacks Equity Research - Zacks Investment Research - Mon Apr 04, 7:05AM CDT
VIVUS Inc. (VVUS) was a big mover last session, as the company saw its shares rise more than 6% on the day.
VVUS: 1.26 (-0.04)

4 Best Biotech Stocks of the First Quarter of 2016
Zacks Equity Research - Zacks Investment Research - Fri Apr 01, 9:03AM CDT
Don't miss these best biotech stocks of the first quarter of 2016.
CRMD: 2.72 (+0.01), MESO: 7.07 (+0.16), GILD: 86.15 (-0.57), SHPG: 192.14 (+2.10), AMGN: 159.19 (-0.68), BXLT: 46.02 (-0.18), KIN: 4.05 (-0.01)

Dr. Reddy's Acquires Anticancer Drug Rights from Eisai
Zacks Equity Research - Zacks Investment Research - Fri Apr 01, 8:40AM CDT
Dr. Reddy's Laboratories (RDY) announced that it has entered into a licensing agreement with Eisai Co., Ltd, Japan.
AMAG: 21.57 (-0.62), RDY: 46.97 (-0.10), XNPT: 7.07 (+0.03)

Jazz's Hepatic VOD Drug Defitelio Gains FDA Nod, Shares Up
Zacks Equity Research - Zacks Investment Research - Thu Mar 31, 3:40PM CDT
Jazz Pharmaceuticals' (JAZZ) shares gained 2.6% after the FDA approved the company's hepatic VOD drug Defitelio.
JAZZ: 152.75 (-3.24), SCMP: 11.99 (-0.42), ANIK: 47.49 (-0.22)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Driven Tech Lands on 2026 CRN AI Innovators List

New Milestone for Driven Tech in AI Innovation If there's one thing that's becoming crystal clear in the tech world, it's this: AI isn't just a flashy add-on anymore. Companies are diving deep into AI waters, transforming their business strategies from the ground up. Driven Tech, Inc., is doing just that, and their efforts haven't gone unnoticed—they’ve made it onto...

Clarivate Taps Global Appetite for AI Research Tools

A Growing Global Thirst for AI-Enhanced Research It looks like the folks at Clarivate have struck a chord. Their Web of Science Research Intelligence platform is garnering attention across the globe, embraced by more than 100 institutions spanning 25 countries. When you craft something that taps into a core need, well, people will jump on it—and that's exactly what's...

PKGD Group's Agave Spirits Surge 56% in 2026 Growth'

PKGD Group's Impressive Growth Story Sometimes you read a report and it genuinely knocks the wind out of you—not because it’s unusual, but because it’s rare to see such robust numbers in a market that ain't exactly all sunshine and rainbows. PKGD Group, the brain behind some damn fine agave spirits, decided to take no prisoners this year, reporting a jaw-dropping...

ELEGOO's M1 Ultra: Bridging Gap in 3D Scanning Tech

A Leap in 3D Scanning: Say Hello to M1 Ultra ELEGOO isn't just fiddling with a toy here—this Shenzhen-based juggernaut is rolling out the M1 Ultra on October 29, 2026, and it's causing quite a stir. While the stock market doesn't see immediate tremors from every shiny new gadget, there’s something to say when a company that pulled over $300 million in sales last year...

Rznomics Advances with EU Orphan Status for RZ-001

RZ-001's European Success: A New Frontier Look, when a biopharmaceutical firm's RNA-editing therapy snags an Orphan Medicinal Product Designation from the European Commission, it's not just some clipboard milestone—it's a heavy-hitter move. That's exactly what Rznomics, the South Korean gene therapy player, pulled off with RZ-001. Now, we aren't just seeing paperwork...

Durabook R12 Tablet: A Rugged Revolution for AI Tasks

Edge AI Gets a Rugged Boost with Durabook's R12 In a world teeming with tech gadgets that crumble at the first sign of a challenge, Durabook's R12 Rugged Tablet makes a solid entrance. This ain't your everyday pretty gadget. Think of it as the big, burly bodyguard of tablets, ready to box through harsh environments without dropping a pixel. What’s stirring the pot this...

When Families Should Consider Life Insurance Plans

Let’s talk about why life insurance isn’t just for those walking around with gray hair. K.D. the Insurance Queen from Centennial, Colorado, dishes out the clearest advice on when and why families ought to have it in their arsenal. A New Mindset on Life Insurance Some folks out there think life insurance is something you ponder in your twilight years. But here’s the...

Hims & Hers Faces Class Action: Investor Implications

Serious Scrutiny for Hims & Hers There's trouble in paradise, folks. Hims & Hers Health, Inc. (NYSE: HIMS) just landed in hot water, and it's not the soothing kind. We're talking about allegations of privacy violations and deceptive practices that have sent ripples—or more like waves—across the investor pond. If you're holding shares, you've probably felt the jolt...

UMC and AP Memory Boost Power with New AI Chips

Breaking Ground in Data Center Power Every so often, the tech industry gets a jolt of innovation that turns heads—not just for what it can do today, but for what it promises tomorrow. This time, it's United Microelectronics Corporation (UMC) and AP Memory shaking things up with their collaboration aimed at redefining power delivery for AI and high-performance computing...

AuraQuantic Leads SPARK Matrix™ in 2026 IPO Ranking

Not Just Another Day in Tech When tech outfits make headlines, it's often because of a shiny new gadget or some jarring security breach. Today, it's AuraQuantic getting their well-deserved spotlight, having snagged the leader's spot in the SPARK Matrix™ for Intelligent Process Orchestration (IPO). You might be wondering what makes this accolade worth attention in a...